Abstract | BACKGROUND: Functional dyspepsia is a prevalent condition associated with diminished quality of life (QoL) and high economic burden. AIM: METHODS: Patients met the Rome III criteria for functional dyspepsia and a validated questionnaire was used to exclude those with anxiety or depression. Moreover, patients had to have failed a trial of acid-suppressive therapy and Helicobacter pylori eradication when positive. End points included subjective global symptom relief and QoL assessed by the Nepean Dyspepsia Index (NDI). RESULTS: Twenty-five patients (14 females, 11 males; mean age = 34.3 +/- 9.9 years) were enrolled and 24 completed the 8-week study. There was a significant improvement in subjective global symptom relief with F + M vs. placebo (ITT: 73.9% vs. 26.1%, P = 0.001) and a significant drop in the NDI score vs. placebo (ITT: -9.0 +/- 11.9 vs. -2.4 +/- 8.9, P = 0.03). No difference was noted whether the initial treatment was F + M or placebo. No significant side effects were noted. CONCLUSIONS: A combination of F and M is safe and effective in the short-term treatment of functional dyspepsia. F + M is associated with significant improvement in QoL independent of the presence of anxiety or depression.
|
Authors | J G Hashash, H Abdul-Baki, C Azar, I I Elhajj, L El Zahabi, H F Chaar, A I Sharara |
Journal | Alimentary pharmacology & therapeutics
(Aliment Pharmacol Ther)
Vol. 27
Issue 11
Pg. 1148-55
(Jun 01 2008)
ISSN: 1365-2036 [Electronic] England |
PMID | 18331614
(Publication Type: Journal Article, Randomized Controlled Trial)
|
Chemical References |
- Anthracenes
- Antipsychotic Agents
- melitracene
- Flupenthixol
|
Topics |
- Adult
- Anthracenes
(therapeutic use)
- Antipsychotic Agents
(therapeutic use)
- Cross-Over Studies
- Drug Therapy, Combination
- Dyspepsia
(drug therapy)
- Female
- Flupenthixol
(therapeutic use)
- Humans
- Male
- Statistics as Topic
|